HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Syndecan-1 in the mouse parietal peritoneum microcirculation in inflammation.

AbstractBACKGROUND:
The heparan sulfate proteoglycan syndecan-1 (CD138) was shown to regulate inflammatory responses by binding chemokines and cytokines and interacting with adhesion molecules, thereby modulating leukocyte trafficking to tissues. The objectives of this study were to examine the expression of syndecan-1 and its role in leukocyte recruitment and chemokine presentation in the microcirculation underlying the parietal peritoneum.
METHODS:
Wild-type BALB/c and syndecan-1 null mice were stimulated with an intraperitoneal injection of Staphylococcus aureus LTA, Escherichia coli LPS or TNFα and the microcirculation of the parietal peritoneum was examined by intravital microscopy after 4 hours. Fluorescence confocal microscopy was used to examine syndecan-1 expression in the peritoneal microcirculation using fluorescent antibodies. Blocking antibodies to adhesion molecules were used to examine the role of these molecules in leukocyte-endothelial cell interactions in response to LTA. To determine whether syndecan-1 co-localizes with chemokines in vivo, fluorescent antibodies to syndecan-1 were co-injected intravenously with anti-MIP-2 (CXCL2), anti-KC (CXCL1) or anti-MCP-1 (CCL2).
RESULTS AND CONCLUSION:
Syndecan-1 was localized to the subendothelial region of peritoneal venules and the mesothelial layer. Leukocyte rolling was significantly decreased with LPS treatment while LTA and TNFα significantly increased leukocyte adhesion compared with saline control. Leukocyte-endothelial cell interactions were not different in syndecan-1 null mice. Antibody blockade of β2 integrin (CD18), ICAM-1 (CD54) and VCAM-1 (CD106) did not decrease leukocyte adhesion in response to LTA challenge while blockade of P-selectin (CD62P) abrogated leukocyte rolling. Lastly, MIP-2 expression in the peritoneal venules was not dependent on syndecan-1 in vivo. Our data suggest that syndecan-1 is expressed in the parietal peritoneum microvasculature but does not regulate leukocyte recruitment and is not necessary for the presentation of the chemokine MIP-2 in this tissue.
AuthorsPaulina M Kowalewska, Amanda L Patrick, Alison E Fox-Robichaud
JournalPloS one (PLoS One) Vol. 9 Issue 9 Pg. e104537 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID25184228 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies
  • CD18 Antigens
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Chemokine CXCL1
  • Chemokine CXCL2
  • Cxcl1 protein, mouse
  • Cxcl2 protein, mouse
  • Lipopolysaccharides
  • P-Selectin
  • Sdc1 protein, mouse
  • Syndecan-1
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • Intercellular Adhesion Molecule-1
Topics
  • Animals
  • Antibodies (administration & dosage)
  • CD18 Antigens (genetics, immunology)
  • Cell Movement
  • Chemokine CCL2 (antagonists & inhibitors, genetics, immunology)
  • Chemokine CXCL1 (antagonists & inhibitors, genetics, immunology)
  • Chemokine CXCL2 (antagonists & inhibitors, genetics, immunology)
  • Endothelial Cells (immunology, pathology)
  • Gene Expression
  • Inflammation (chemically induced, genetics, immunology, pathology)
  • Injections, Intraperitoneal
  • Intercellular Adhesion Molecule-1 (genetics, immunology)
  • Leukocytes (immunology, pathology)
  • Lipopolysaccharides (administration & dosage)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • P-Selectin (antagonists & inhibitors, genetics, immunology)
  • Peritoneum (blood supply, immunology, metabolism, pathology)
  • Syndecan-1 (antagonists & inhibitors, genetics, immunology)
  • Tumor Necrosis Factor-alpha (administration & dosage)
  • Vascular Cell Adhesion Molecule-1 (genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: